Trial · NCT06680921
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival(PFS) , as assessed by blinded independent review committee(BIRC) according to RECIST1.1 | 2 year | PFS was defined as the time from the date of randomization to the first documented disease progression or death from any cause, whichever occurrs first. |
| Secondary | Progression free survival(PFS) , as assessed by investigator according to RECIST1.1 | 2 year | PFS was defined as the time from the date of randomization to the first documented disease progression or death from any cause, whichever occurrs first. |
| Secondary | Overall Survival (OS) | 3 year | OS is the time from the date of randomization to death from any cause. |
| Secondary | The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) | 3 year | Frequency and severity of Adverse Events or Serious Adverse Events as defined by CTCAE version 5.0 |
| Secondary | Blood concentrations | At five specified time points of the first 6 cycles (each cycle is 28 days) | Blood concentrations of SIM0270 and everolimus |
| Secondary | Objective Response Rate (ORR) by investigator | 2 year | The objective response rate is defined as the percentage of subjects with a complete response or partial response. |
| Secondary | Objective Response Rate (DOR) by investigator | 2 year | The DoR is defined as the time from the date of first complete or partial response until the date of documented progression or death from any cause. |
| Secondary | ORR by BIRC | 2 year | The objective response rate is defined as the percentage of subjects with a complete response or partial response. |
| Secondary | DOR by BIRC | 2 year | The DoR is defined as the time from the date of first complete or partial response until the date of documented progression or death from any cause. |
| Secondary | Clinical benefit rate(CBR) by investigator | 2 year | The clinical benefit rate is defined as the percentage of subjects with a complete response or partial response or stable disease for ≥24 weeks. |
| Secondary | CBR by BIRC | 2 year | The clinical benefit rate is defined as the percentage of subjects with a complete response or partial response or stable disease for ≥24 weeks. |
| Secondary | Time To Progression (TTP) by investigator | 2 year | TTP is defined as the time from randomization until the date of first documented progression. |
| Secondary | Time To Progression (TTP) by BIRC | 2 year | TTP is defined as the time from randomization until the date of first documented progression. |
| Secondary | Change from baseline in EQ-5D-5L scores | 2 year | Change from baseline in EQ-5D-5L scores |
| Secondary | Change from baseline in FACT-B scores | 2 year | Change from baseline in FACT-B scores |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06680921/registered